Roivant's Pulmovant reports positive mosliciguat Phase 2 data in PH-ILD, topping Wall Street's bar for Phase 3 advancement.
Roivant Sciences said Tuesday its inhaled drug candidate has passed a mid-stage test in interstitial lung disease, surpassing Wall Street’s benchmarks for success.
In the …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Roche’s lung cancer drug candidate divarasib has beaten marketed drugs from Amgen and Bristol Myers Squibb in a head-to-head…
(Bloomberg) -- Roche Holding AG’s experimental lung cancer pill outperformed two approved medicines in a late-stage study,…
FDA approves Roivant's Lisraya (brepocitinib), first oral drug for dermatomyositis; TD Cowen sees $5B–$10B potential across…
Pfizer's Litfulo wins Phase 3 for vitiligo; Braveheart Bio eyes $275M IPO testing Hengrui drug; Attovia targets $182M IPO; Pfizer…
Swiss pharmaceutical and diagnostics giant Roche announced the success of a pivotal clinical trial for its drug divarasib in the…
Though not without a bump along the way, Roivant-backed Priovant Therapeutics has pushed its dual TYK2/JAK1 inhibitor across the…
